Clinical experiment designed to assess clinical efficacy targeting N/A in TRD patients. Primary outcome: antidepressant efficacy with improved side effect profile
Preliminary clinical investigation of arketamine (R-ketamine) as a potential improvement over racemic ketamine and esketamine for treatment-resistant depression. This early-phase study examined the R-enantiomer of ketamine, which preliminary data suggested might offer advantages including longer-lasting antidepressant effects, reduced psychomotor adverse effects, and lower potential for substance abuse. The research compared the efficacy, safety, and tolerability profile of arketamine against established ketamine formulations, with particular attention to psychotomimetic side effects and abuse liability that are concerns with current ketamine treatments.
Administration of arketamine with comparison to ketamine/esketamine for efficacy and adverse effects
Longer-lasting antidepressant effects with fewer psychomotor side effects and lower abuse potential
Superior or equivalent antidepressant efficacy with improved tolerability profile compared to existing ketamine formulations
No related hypotheses
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.